drugset

drugset / Trial / NCT03678675

Increased Ketorolac Administration After Cesarean Section and Its Effect on Opioid Use: a Randomized Control Trial

NCT03678675 ↗

Phase 3 Completed 148 enrolled Tufts Medical Center

RandomizedParallel-groupTriple-blindTreatment

Summary

To evaluate the efficacy of increased ketorolac in reducing opioid use after cesarean section.

Timeline

Start: 2019-05-30
Primary completion: 2022-01-31
Completion: 2022-06-30

Publications

Hostage J, Kolettis D, Sverdlov D, Ludgin J, Drzymalski D, Sweigart B, Mhatre M, House M. Increased Scheduled Intravenous Ketorolac After Cesarean Delivery and Its Effect on Opioid Use: A Randomized Controlled Trial. Obstet Gynecol. 2023 Apr 1;141(4):783-790. doi: 10.1097/AOG.0000000000005120. Epub 2023 Mar 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketorolac	Other / unclassified	30 mg	Intravenous

Indications